Vanderbilt Vasculitis Center Registry and Repository (VVCRR)
Vasculitis type: All forms of systemic vasculitis.
The goal of the VVCRR is to provide an infrastructure for the support of investigator-initiated studies for patients with systemic vasculitis. The VVCRR is a longitudinal, observational registry which collects clinical information of patients with systemic vasculitis. Participants have the option of giving blood samples at the time of routine blood work done at Vanderbilt University Medical Center.
Contact – Research Coordinator
Pamela Krueger - pamela.krueger@vumc.org
615-875-8356
ABAGART: for Giant Cell Arteritis Patients
Principal Investigator - Kevin Byram, MD
Co-Investigator - Jason Springer, MD, MS
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. We are enrolling eligible patients 50 years of age or older, who have newly diagnosed or relapsing GCA within 8 weeks prior to screening to be randomized at a 1:1 ratio to receive subcutaneous abatacept 125mg/week or placebo. All patients will receive glucocorticoids (GC) which will be tapered and discontinued by week 26 according to a standardized schedule. Patients who achieve remission will remain on their blinded assignment for 12 months at which time abatacept/placebo will be stopped. Patients who do not achieve remission by Month 3, or who experience a relapse within the first 12 months will have the option of receiving open-label abatacept for a maximum of 12 months.
Contact – Research Coordinator
Pamela Krueger - pamela.krueger@vumc.org
615-875-8356
B-Cell Large Vessel Vasculitis: Giant cell arteritis and Takayasu's arteritis
PI: Jason Springer MD MS, Associate Professor, Rheumatology Division
Sub-Investigator: Kevin Byram MD, Associate Professor of Medicine, Director-Vanderbilt Vasculitis Clinic, Rheumatology Division
This study will look at the mechanisms that drive autoreactive B cell (ABC) expansion or differentiation into effector populations in large vessel vasculitis have not been identified. We will study patients with this clinical syndrome recruited from the Vasculitis Center of Excellence at Vanderbilt University Medical Center.
Contact – Research Coordinator
Pamela Krueger - pamela.krueger@vumc.org
615-875-8356
ABROGATE: Granulomatosis with Polyangiitis
PI: Narender Annapureddy, MD, Associate Professor, Rheumatology Division
Sub Investigators: Kevin Byram, MD, Associate Professor of Medicine, Director-Vanderbilt Vasculitis Clinic, Rheumatology Division
Jason Springer, MD, Associate Professor, Rheumatology Division
Abatacept for relapsing patients with Granulomatosis with Polyangiitis (Wegener's disease) This is a Multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of abatacept to achieve sustained glucocoritocoid-free remission in patients with relapsing non-severe GPA.
Contact – Research Coordinator
Pamela Krueger - pamela.krueger@vumc.org
615-875-8356